James Noble

Evolve Capital Plc operates as a closed-end investment fund/investment trust. Its principal activity is to invest in equities, convertible or non-convertible debt, options and warrants in companies which are quoted on intending to join, the PLUS-quoted market by way of an IPO. The company was founded on November 27, 2007 and is headquartered in London, the United Kingdom.

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Anthra Pharmaceuticals, Inc. is an American company.

BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom.

Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom.

Part of Commerzbank AG, Commerzbank Finance Ltd. is a British company that provides securities brokerage services. The private company is based in London, UK. Commerzbank Finance was founded in 1955.

Astaire Group Ltd. provides investment banking services. The company was founded in 1984 and is headquartered in Colchester, the United Kingdom.

Axellis, Inc. sells and distributes medical devices. Its products are used for oncology and cardiology. The company was founded in August 2007 and is headquartered in London, UK

Finsbury Worldwide Pharmaceutical Trust Plc provides investment on pharmaceutical and biotechnology sector on a global scale. It reduces risk through extensive fundamental research, worldwide exposure, position limits and balanced market capitalisations. The company was founded in 1995 and is headquartered in London, the United Kingdom.

Albany Capital plc is an activist and pre-IPO investment. It is a co-investor and principal alongside other institutions in private and listed companies using private equity techniques in order to achieve a medium term return. The company is headquartered in London, the United Kingdom.

Northland Capital Partners Ltd. provides investment banking services. The private company is based in London, UK. and has subsidiaries in United Kingdom. The British company was founded in 1991. Robert Alan Johnson has been the CEO of the company since 2010.

China Food Co. Plc engaged in the development, manufacture and distribution of cooking and dipping sauces and animal feed products It offers consumer condiments such as soya sauce, vinegar, bean paste, pickled products, chilli oil, and flavour enhancers; and animal feeds such as compound feed, concentrate feed, and premix. The company was founded in November 1994 and was headquartered in London, the United Kingdom.

MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA.

Oxfordshire Biotechnet Ltd. is a venture capital fund.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

AfriAg Global Plc engages in investing by seeking to acquire a direct and indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. It focuses on opportunities in Africa, Europe, and the Middle East. The company was founded on June 17, 2008 and is headquartered in London, the United Kingdom.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom.

Ingenox Therapeutics Ltd. provides cancer treatment services. The private company is based in Oxford, UK. The CEO of the British company is Nick la Thangue.